#### (19) World Intellectual Property Organization

International Bureau



# T TREAT BUILDING OF BUILDING BUILD BUILD BUILDING BUILDING

(43) International Publication Date 20 October 2005 (20.10.2005)

**PCT** 

(10) International Publication Number WO 2005/097832 A3

(51) International Patent Classification<sup>7</sup>: A61K 39/395

C07K 16/22,

(21) International Application Number:

PCT/US2005/010994

(22) International Filing Date: 31 March 2005 (31.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/558,290 31 March 2004 (31.03.2004) U-

(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ADAMS, Camellia, W. [US/US]; 116C Flynn Avenue, Mountain View, CA 94043 (US). FERRARA, Napoleone [US/US]; #704, 2090 Pacific Avenue, San Francisco, CA 94109 (US). FILVAROFF, Ellen [US/US]; 538 18th Avenue, San Francisco, CA 94121 (US). MAO, Weiguang [CN/US]; 1613 De Anza Blvd., San Mateo, CA 94403 (US). PRESTA, Leonard, G. [US/US]; #206, 1900 Gough Street, San Francisco, CA 94109 (US). TEJADA, Max, L. [CA/US]; 121B Redding Road, Campbell, CA 95008 (US).
- (74) Agent: HASAK, Janet, E.; Genentech, Inc., MS 49, South San Francisco, CA 94080 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


#### **Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 1 December 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMANIZED ANTI-TGF-BETA ANTIBODIES

#### aTGFb1 treated B16 Tumor Growth



(57) Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.

Internation No
PCT/US2005/010994

			C1/U32U05/U1U994		
A. CLASSIF	FICATION OF SUBJECT MATTER CO7K16/22 A61K39/395		-		
	International Patent Classification (IPC) or to both national classifi	cation and IPC			
	SEARCHED (5.1)	Management of A			
Minimum do	currentation searched (classification system followed by classification ${\tt C07K}$	шоп зутроіѕ)			
Documentati	ion searched other than minimum documentation to the extent that	such documents are included	in the fields searched		
	ata base consulted during the international search (name of data b		arcri terms used)		
EPO-Int	ternal, WPI Data, Sequence Search,	RIOSIS' EMBASE	i j		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.		
Υ	US 2003/064069 A1 (THOMPSON JULI ELIZABETH ET AL) 3 April 2003 (2	A 1003-04-03)	1–58		
	abstract; claims 1-26	.505 07 00/			
,	paragraph '0077! - paragraph '00	78!			
Υ	US 5 821 337 A (CARTER ET AL)		1-58		
	13 October 1998 (1998-10-13) abstract; claim 13				
		-/	,		
<u> </u>					
	her documents are listed in the continuation of box C.	Patent family men	nbers are listed in annex.		
<b>l</b> '	ategories of cited documents :	"T" later document publishe	ed after the international filing date It in conflict with the application but		
consid	ent defining the general state of the art which is not dered to be of particular relevance	cited to understand the invention	e principle or theory underlying the		
filing d		"X" document of particular cannot be considered	relevance; the claimed invention novel or cannot be considered to		
which	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another near the specified by the specified of a specified by the specified by	involve an inventive st "Y" document of particular	tep when the document is taken alone relevance; the claimed invention		
"O" docume	n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	cannot be considered document is combined	to involve an inventive step when the d with one or more other such docu-		
"P" docume	means ent published prior to the international filing date but han the priority date claimed	in the art.	ments, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family		
	actual completion of the international search		nternational search report		
1	.4 October 2005	21/10/200	5		
Name and r	mailing address of the ISA	Authorized officer			
	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk				
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Favre, N			

Internation No
PCT/US2005/010994

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HOEFER M ET AL: "ANTI-(TRANSFORMING GROWTH FACTOR BETA) ANTIBODIES WITH PREDEFINED SPECIFICITY INHIBIT METASTASIS OF HIGHLY TUMORIGENIC HUMAN XENOTRANSPLANTS IN NU/NU MICE" CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 41, no. 5, 1995, pages 302-308, XP000644718 ISSN: 0340-7004 cited in the application the whole document	1-58
Υ	US 5 772 998 A (DASCH ET AL) 30 June 1998 (1998-06-30) cited in the application the whole document	1-58
Υ	US 2002/176858 A1 (DASCH JAMES R ET AL) 28 November 2002 (2002-11-28) the whole document	1–58
Υ .	US 2002/051785 A1 (SLAMON DENNIS J ET AL) 2 May 2002 (2002-05-02) the whole document	1–58
A	KLOS K S ET AL: "COMBINED TRASTUZUMAB AND PACLITAXEL TREATMENT BETTER INHIBITS ERBB-2-MEDIATED ANGIOGENESIS IN BREAST CARCINOMA THROUGH A MORE EFFECTIVE INHIBITION OF AKT THAN EITHER TREATMENT ALONE" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 98, no. 7, 1 October 2003 (2003-10-01), pages 1377-1385, XP001206049 ISSN: 0008-543X the whole document	1-58
Α	WO 00/34337 A (TSUKUBA RESEARCH LABORATORY, TOAGOSEI CO., LTD; PROTEIN DESIGN LABS, I) 15 June 2000 (2000-06-15) the whole document	54-58
А	GOLD L I: "THE ROLE FOR TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA) IN HUMAN CANCER" CRITICAL REVIEWS IN ONCOGENESIS, BOCA RATON, FL, US, vol. 10, no. 4, 1999, pages 303-360, XP001038678 ISSN: 0893-9675 the whole document	1–58

Internation No PCT/US2005/010994

		1 01/ 03/2003/ 010992	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to c	loim No
Category °	Citation of document, with indication, where appropriate, of the relevant passages	helevani lo c	aim No.
A	US 2003/125251 A1 (WAKEFIELD LALAGE M ET AL) 3 July 2003 (2003-07-03) the whole document	1-58	3
<b>A</b>	PRESTA L G ET AL: "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 20, 15 October 1997 (1997-10-15), pages 4593-4599, XP002111212 ISSN: 0008-5472 the whole document	1-58	3
E	WO 2005/050200 A (GENENTECH, INC; FILVAROFF, ELLEN, H) 2 June 2005 (2005-06-02) the whole document	1-58	3

# International application No.

### **INTERNATIONAL SEARCH REPORT**

PCT/US2005/010994

Box	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)	
1.	With inver	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ntion, the international search was carried out on the basis of:	
	a.	type of material	
		X a sequence listing	
		table(s) related to the sequence listing	
	b.	format of material	
		X in written format	ļ
		X in computer readable form	
	0	time of filing/furnishing	
	c.	contained in the international application as filed	
		filed together with the international application in computer readable form	
		x furnished subsequently to this Authority for the purpose of search	
2.	Х	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	
3.	Addi	itional comments:	

### International application No. PCT/US2005/010994

### INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Int	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.:  — because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 34-49 and 54-58 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
•	
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	k on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Information on patent family members

Interisconal Application No PCT/US2005/010994

	<del></del>				<del></del> -	<del> </del>
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2003064069	A1	03-04-2003	US US	2003091566 A1 6492497 B1		15-05-2003 10-12-2002
US 5821337	A	13-10-1998	AT AU CA DE DE DK EP JP LU NL WO US US	255131 T 675916 B2 2250992 A 2103059 A1 69233254 D1 69233254 T2 590058 A1 2206447 T3 6508267 T 2005000169 A 91067 A9 300145 I1 9222653 A1 6407213 B1 6719971 B1 6639055 B1	1 1 2 3 1 3 1 1 1 1	15-12-2003 27-02-1997 12-01-1993 15-12-1992 08-01-2004 16-09-2004 29-03-2004 06-04-1994 16-05-2004 22-09-1994 06-01-2005 02-04-2004 01-06-2004 23-12-1992 18-06-2002 13-04-2004 28-10-2003
US 5772998	Α	30-06-1998	US	5783185 A		21-07-1998
US 2002176858	A1	28-11-2002	NONE			
US 2002051785	A1 ·	02-05-2002	NONE			
WO 0034337	A	15-06-2000	NONE			
US 2003125251	A1	03-07-2003	NONE	· · · · · · · · · · · · · · · · · · ·		
WO 2005050200		02-06-2005	NONE			